HUNTSVILLE, July 01, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company, today announced that its Board of Directors has established November 7, 2025, as the date of its 2025 annual meeting of stockholders (the “Annual Meeting”). The time and location of the Annual Meeting will be set forth in the Serina’s definitive proxy statement for the Annual Meeting to be filed with the Securities and Exchange Commission (the “SEC”). Because the d ...

How Parkinson’s affects million – and why current treatments are not enoughContinuous dopaminergic stimulation (CDS): a next-gen approach to Parkinson’s careSerina’s drug candidate SER-252 is designed to deliver continuous symptom reliefJoin Serina CEO Steve Ledger for this live event hosted by FORCE Family Office HUNTSVILLE, AL, June 23, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug op ...

Core Insights - Serina Therapeutics, Inc. has announced a strategic partnership with Juvenescence Ltd., which has successfully closed the first tranche of a $76 million Series B financing round, targeting a total of $150 million [2][3] - The partnership aims to establish a drug development hub in Abu Dhabi, integrating AI-enabled drug discovery with advanced clinical infrastructure to expedite the development of innovative therapeutics [3][4] - Serina is focused on developing its proprietary POZ Platform™ for drug optimization, targeting neurological diseases and other indications, and is positioned as a core portfolio company of Juvenescence [5][4] Company Overview - Serina Therapeutics is a clinical-stage biotechnology company headquartered in Huntsville, Alabama, specializing in drug candidates for neurological diseases and other conditions [5] - The POZ Platform™ developed by Serina has the potential to enhance the efficacy and safety profiles of various therapeutic modalities, including small molecules and RNA-based therapeutics [5] - Juvenescence, the strategic partner, is an AI-enabled biotech company focused on developing medicines to extend healthy lifespan by targeting aging mechanisms [7][9] Strategic Partnerships - The collaboration between Juvenescence and M42, a global health company based in Abu Dhabi, signifies a commitment to building a leading life-sciences hub and developing a pipeline of innovative therapeutics [4][11] - M42 operates over 480 facilities across 26 countries and employs more than 20,000 people, integrating advanced technologies in healthcare [12]

Core Insights - Serina Therapeutics congratulates its strategic partner Juvenescence Ltd. for securing $150 million in Series B financing led by M42, which will enhance their drug development capabilities [1][2][3] - The partnership aims to establish a drug development hub in Abu Dhabi, integrating AI-enabled drug discovery with advanced clinical infrastructure to expedite the creation of innovative therapies targeting age-related diseases [2][3] - Juvenescence's leadership has a proven track record in biopharma, having previously led significant deals and developed medicines with peak annual sales totaling $30 billion [7][8] Company Overview - Serina Therapeutics is a clinical-stage biotechnology company focused on developing drug candidates for neurological diseases and other indications, utilizing its proprietary POZ Platform to enhance the efficacy and safety of various therapeutic modalities [4] - Juvenescence is an AI-enabled biotech company dedicated to extending healthy lifespan by targeting core aging mechanisms to treat age-related diseases [6][8] - M42, a global health company, combines AI, technology, and genomics to innovate healthcare solutions, operating over 480 facilities across 26 countries [9][11]

Company Overview - Serina Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing drug candidates for neurological diseases and other indications using its proprietary POZ Platform™ technology [7] - The company is headquartered in Huntsville, Alabama, on the campus of the HudsonAlpha Institute of Biotechnology [7] Industry Context - The biotechnology sector is currently experiencing a bear market, with approximately 25% of the 700 to 800 publicly traded US biotech companies having negative enterprise values [3] - The upcoming webinar event titled "Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?" aims to discuss investment opportunities in this challenging environment [2][3] Event Details - Serina's CEO, Steven A. Ledger, will present at the Tribe Public's Webinar on June 11, 2025, at 8:30 am Pacific / 11:30 am Eastern [2] - Participants can submit questions for the CEO before and during the event, which will be hosted by Tribe Public's Managing Member, John F. Heerdink, Jr. [6]

Company Overview - Serina Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing a pipeline of drug candidates for neurological diseases and other indications, utilizing its proprietary POZ Platform for drug optimization [5]. Leadership Appointment - Dr. Stephen Brannan has been appointed to the Board of Directors, bringing over 30 years of experience in neuroscience and neuropsychiatry drug development [2][3]. - Dr. Brannan previously served as Chief Medical Officer at Karuna Therapeutics, where he led the clinical strategy for KarXT, a groundbreaking therapy for schizophrenia that contributed to Karuna's $14 billion acquisition by Bristol Myers Squibb in 2024 [2][3]. Strategic Focus - The company aims to advance long-acting treatments for movement disorders and other CNS conditions, aligning with Dr. Brannan's expertise in designing data-driven clinical trials and understanding patient and commercial needs [3]. Previous Experience - Dr. Brannan has held senior roles at Takeda, Novartis, Cyberonics (now LivaNova), and Eli Lilly, directing clinical development programs in various CNS conditions [3]. - He is a founding member of the CNS Summit Leadership Council and has served on the Executive Committee of the International Society for CNS Clinical Trials and Methodology (ISCTM) [3]. Board Changes - Remy Gross has departed from the Board of Directors, with the company expressing gratitude for his contributions during its transition from a private to a public entity [5].

Core Insights - Serina Therapeutics is making significant progress in developing its proprietary POZ Platform for drug optimization, particularly focusing on SER-252 for advanced Parkinson's care [2][3] - The company has secured $15 million in equity financing, enhancing its financial foundation to support ongoing clinical trials and research initiatives [7] - Recent data presented at a summit indicates that Serina's POZ-lipid technology may lead to safer and more effective lipid nanoparticle formulations for gene therapy [7] Recent Highlights - The company is on track to dose the first patient in the Phase 1b clinical trial of SER-252 by Q4 2025 [6] - Two experienced biotech leaders have been added to the Board of Directors, enhancing corporate strategy and business development capabilities [7] - The POZ Platform is being advanced across multiple therapeutic modalities, including neurological disorders and RNA-based therapeutics [2][7] First Quarter Operating Results - Revenues for Q1 2025 were not material, similar to Q1 2024 [4] - Operating expenses increased to $5.9 million in Q1 2025 from $2.3 million in Q1 2024, driven by higher R&D and administrative costs [4][6] - R&D expenses rose to $3.0 million in Q1 2025, up from $1.1 million in Q1 2024, primarily due to increased headcount and professional fees [5] Financial Performance - The net loss for Q1 2025 was $4.8 million, or $(0.49) per share, compared to a net loss of $15.0 million, or $(5.38) per share, in Q1 2024 [10][22] - Other income for Q1 2025 was $1.0 million, a significant improvement from a net expense of $12.7 million in Q1 2024 [9][22] - Cash and cash equivalents totaled $4.3 million as of March 31, 2025, with projections indicating sufficient funds to last through Q3 2025 [11] Liquidity Information - The company has a strengthened balance sheet following recent financing, which includes a $10 million investment from JuvVentures and a $5 million private placement [7][11] - Total current assets as of March 31, 2025, were $5.8 million, with total liabilities at $5.2 million [20][21]

Financial Performance - Revenues for the first quarter of 2025 were not material, remaining at $0 compared to $5,000 in the same period of 2024[4] - Operating expenses increased to $5.9 million in Q1 2025 from $2.3 million in Q1 2024, representing a 155% increase[4] - Research and development expenses rose to $3.0 million in Q1 2025, up from $1.1 million in Q1 2024, marking a 173% increase[5] - General and administrative expenses were $2.9 million in Q1 2025, compared to $1.2 million in Q1 2024, reflecting a 142% increase[6] - The net loss attributable to Serina for Q1 2025 was $4.8 million, or $(0.49) per share, significantly improved from a net loss of $15.0 million, or $(5.38) per share, in Q1 2024[10] - Net loss for the three months ended March 31, 2025, was $4.822 million, compared to a net loss of $15.015 million for the same period in 2024[25] Cash Flow and Financing - Cash and cash equivalents totaled $4.3 million as of March 31, 2025, with projections indicating sufficient funds to last through Q3 2025[11] - Serina secured $15 million in equity financing since late 2024, including a $10 million investment from JuvVentures and a $5 million private placement[7] - Net cash used in operating activities increased to $4.322 million from $1.577 million year-over-year[25] - Cash and cash equivalents at the end of the period were $4.267 million, down from $8.756 million at the end of the same period in 2024[25] - Net cash provided by financing activities was $4.917 million, compared to $2.728 million in the previous year[25] - The company drew down on loan facilities from Juvenescence, resulting in no cash outflow reported for the current period[25] Operational Developments - The company is on track to dose the first patient in the Phase 1b clinical trial of SER-252 for advanced Parkinson's disease by Q4 2025[6] - New data presented at a summit showed Serina's POZ-lipid did not trigger an immune response, indicating potential for safer LNP formulations[7] Changes in Financial Position - Other income for Q1 2025 was $1.0 million, a turnaround from a net expense of $12.7 million in Q1 2024, indicating a $13.7 million improvement[9] - Stock-based compensation increased significantly to $956,000 from $53,000 year-over-year[25] - The company reported a change in fair value of convertible promissory notes, which was $0 in the current period compared to $7.017 million in the previous year[25] - The company had a significant increase in accounts payable, which rose to $441,000 from $244,000 year-over-year[25] - The issuance of common stock upon conversion of Preferred Stock was $0 in the current period, compared to $36.404 million in the previous year[25] - The merger and issuance of common stock upon consummation of the merger on March 26, 2024, resulted in $0 in the current period, compared to $961,000 in the previous year[25]

Financial Performance - The company reported an operating loss of $5.9 million for the three months ended March 31, 2025, compared to a loss of $2.3 million for the same period in 2024, reflecting an increase of $3.6 million [117]. - The company reported net losses of $4.8 million for the three months ended March 31, 2025, compared to a net loss of $15.0 million for the same period in 2024, reflecting a decrease of $10.2 million [138]. - Other income net was $1.0 million for the three months ended March 31, 2025, compared to a net expense of $12.7 million in the same period in 2024, resulting in a $13.7 million improvement [141]. - The net loss for the three months ended March 31, 2025, was $4.8 million, compared to a net loss of $15.0 million in the same period in 2024 [152][154]. Expenses - Research and development expenses increased to $3.0 million for the three months ended March 31, 2025, up from $1.1 million in the same period in 2024, representing a $1.9 million increase [139]. - Total operating expenses for the three months ended March 31, 2025, were $5.9 million, compared to $2.3 million for the same period in 2024, indicating a $3.5 million increase [138]. - General and administrative expenses increased to $2.9 million for the three months ended March 31, 2025, from $1.2 million in the same period in 2024, representing a 141.7% increase [140]. - Net cash used in operating activities for the three months ended March 31, 2025, was $4.3 million, a 174.1% increase from $1.6 million in the same period in 2024 [151]. Cash and Financing - Cash and cash equivalents were reported at $4.3 million as of March 31, 2025 [117]. - As of March 31, 2025, the company had $4.3 million in cash and cash equivalents, with significant financing from the issuance of common stock and convertible notes prior to the merger [144]. - Net cash provided by financing activities for the three months ended March 31, 2025, was $4.9 million, an increase of 80.2% from $2.7 million in the same period in 2024 [155][156]. - The company may need to raise additional capital through equity offerings, debt financings, or other arrangements to fund operations for the foreseeable future [149]. Accumulated Deficit and Future Outlook - The company had an accumulated deficit of $49.1 million as of March 31, 2025 [117]. - The accumulated deficit as of March 31, 2025, was $49.1 million, raising substantial doubt about the company's ability to continue as a going concern [146]. - The company expects to incur substantial expenditures in the foreseeable future for the development of its product candidates and will require additional financing to continue this development [118]. - The company anticipates that research and development expenses, general and administrative expenses, and capital expenditures will continue to increase [148].

Company Overview - Serina Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing a pipeline of wholly owned drug product candidates aimed at treating neurological diseases and other indications [2] - The company is headquartered in Huntsville, Alabama, on the campus of the HudsonAlpha Institute of Biotechnology [2] Technology and Innovation - Serina's proprietary POZ Platform is designed to enhance the integrated efficacy and safety profile of various therapeutic modalities, including small molecules, RNA-based therapeutics, and antibody-based drug conjugates (ADCs) [2] Upcoming Events - Steve Ledger, the CEO of Serina, is scheduled to present at the JonesResearch Hosts: Virtual CNS Day on April 29, 2025, at 12:00 p.m. EDT [1] - A live webcast of the presentation will be available for registered attendees, with an archived replay accessible for 90 days post-event [1]